【ScinoPharm】Announcement of the Board of Directors' approval of the Q1 2026 Consolidated Financial Report

1.Date of board of directors resolution or approval:2026/05/06 2.Date of audit committee approval:2026/04/29 3.Financial report or self-prepared financial information reporting period (YYYY/MM/DD~YYYY/MM/DD):2026/01/01~2026/03/31 4.Operating revenue accumulated from January 1 to the current period (NT$ thousands):659,708 5.Gross profit (gross loss) accumulated from January 1 to the current period (NT$ thousands):221,535 6.Operating profit (loss) accumulated from January 1 to the current period (NT$ thousands):8,488 7.Pre-tax net profit (net loss) accumulated from January 1 to the current period (NT$ thousands):19,325 8.Net profit (net loss) for the current period accumulated from January 1 to the current period (NT$ thousands):16,529 9.Net profit (loss) attributable to owners of the parent company accumulated from January 1 to the current period (NT$ thousands):16,529 10.Basic earnings per share (loss) for the current period accumulated from January 1 to the current period (NT$):0.02 11.Total assets at period end (NT$ thousands):11,860,159 12.Total liabilities at period end (NT$ thousands):1,547,316 13.Equity attributable to owners of the parent company at period end (NT$ thousands):10,312,843 14.Other matters that should be specified:None